Luis Jodar

Luis Jodar

Pfizer Inc. - New York / United States
Others
AD Scientific Index ID: 4386199
-
person_outline Luis Jodar's MOST POPULAR ARTICLES
1-) Impact and effectiveness of mRNA BNT162b2 vaccine against SARS-CoV-2 infections and COVID-19 cases, hospitalisations, and deaths following a nationwide vaccination campaign in …EJ Haas, FJ Angulo, JM McLaughlin, E Anis, SR Singer, F Khan, N Brooks, ...The Lancet 397 (10287), 1819-1829, 202112092021
2-) Effectiveness of mRNA BNT162b2 COVID-19 vaccine up to 6 months in a large integrated health system in the USA: a retrospective cohort studySY Tartof, JM Slezak, H Fischer, V Hong, BK Ackerson, ON Ranasinghe, ...The Lancet 398 (10309), 1407-1416, 20217942021
3-) Serological criteria for evaluation and licensure of new pneumococcal conjugate vaccine formulations for use in infantsL Jódar, J Butler, G Carlone, R Dagan, D Goldblatt, H Käyhty, K Klugman, ...Vaccine 21 (23), 3265-3272, 20034032003
4-) Development of vaccines against meningococcal diseaseL Jódar, IM Feavers, D Salisbury, DM GranoffThe Lancet 359 (9316), 1499-1508, 20023592002
5-) Salmonella paratyphi A rates, AsiaRL Ochiai, XY Wang, L Von Seidlein, J Yang, ZA Bhutta, SK Bhattacharya, ...Emerging infectious diseases 11 (11), 1764, 20052772005